Killing the goose by Donaldson, N
  Version 6, September 4th, 2017 
 
Killing the goose 
The regulatory framework for implanted medical devices is preventing severely impaired people from 
benefitting from rehabilitation research. Consequently, research effort is wasted and we are unable to use 
implants to reduce the costs of healthcare. The framework should be altered so that it is economically 
possible to get new devices for small patient groups into widespread use. 
For clinicians who treat patients with spinal cord injury, establishing satisfactory bladder 
management is a priority. At present, at discharge from hospital, the commonest methods are either 
anticholinergic drugs or botulinum toxin to prevent incontinence, combined with intermittent 
catheterisation to drain the bladder. In a recent British study, the annual cost per patient to the 
National Health Service of these methods was calculated as £7,000 and £8,700 respectively (Hamid, 
2015), which may continue for the remaining decades of the patients’ lives. The side effects of 
anticholinergics are unpleasant and typically patients get many urinary tract infections (UTIs). Is this 
satisfactory when the healthcare budget is so stretched? 
A neuroprosthesis was developed by Brindley in the 1970s for complete-lesion spinal cord-injured 
patients. It allows the user to empty the bladder when convenient by stimulating the sacral motor 
nerve fibres. Implantation of the device is usually accompanied by cutting the sensory fibres because 
this deafferentation prevents incontinence and facilitates stimulator-voiding. The device is very 
simple and very reliable: some patients have implants that are still working well after 30 years. The 
device means that routine use of drugs is unnecessary, the frequency of UTIs is much reduced and 
there are many other urological benefits (Brindley, 1994). Although about 4000 of these devices 
have been implanted world-wide, only a few hospitals now routinely carry out the procedure. 
These implants have been and remain very important to many patients. For example, Sir Philip 
Craven wrote the following. “I have been paraplegic since I was 16, but I have been very active as an 
international wheelchair basketball player and I have been the President of the International 
Paralympic Committee for 14 years. I decided to have a Brindley implant because I used to have so 
many UTIs and it has been brilliant for the past 26 years. It has been absolutely fundamental in 
enabling me to do a lot of long distance air travel which has been essential in order to be an 
effective president.  Without the implant I would have probably been dead now!” 
The reason it has fallen out of favour has been understood for years – it is the other effects of the 
deafferentation, mainly loss of reflex sexual function in men. Obviously there is a need for a new 
type of neuroprosthesis which does not require concomitant deafferentation but is still reliable and 
inexpensive. As a result of research in many labs into methods for suppressing reflex bladder 
contractions, temporarily blocking nerve conduction, and detecting specific afferent nerve traffic 
(Kirkham, 2002; Tai, 2004; Bhadra, 2006; Kilgore, 2014; Metcalfe, 2017), I think that we are now 
close to being able to specify such a device. The aims would be to improve quality of life and also 
reduce healthcare costs for complete-lesion patients. However, there is a new problem. The 
technical difficulties may have almost been overcome but the commercial difficulty of producing 
such devices has increased enormously in the past 30 years. Then it was only necessary to show the 
company how to make the devices in the same way as those made for the first ten patients, and to 
write documents to explain to the surgeons and to the patients respectively what to do with them. 
That was all – the company started selling devices immediately. 
Now, within the EU, companies cannot sell until they have a CE Mark, and that is only awarded after 
a clinical trial has shown efficacy. The trial is not allowed to start until the government agency 
(MHRA in Britain) has been persuaded that the device is safe, which requires a comprehensive 
Technical File with a risk assessment and data showing that the device complies with requisite 
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standards. I do not know what the least cost could be for producing an adequate Technical File from 
scratch but it seems likely to be in the range £1-10M. In 2014, Torax Medical, an American start-up 
company reported (Demarchi J, 2014) that half way through their 100-subject European trial they 
had spent $50M, this expenditure against a loan by investors. The product has now been 
‘discontinued’ due to a ‘business decision’ (www.toraxmediacl.com/fenix). 
 After completing the trial the company can apply for a CE Mark. This requires further expense, now 
making an application to a different organisation (a Notified Body) which is neither limited in the 
time it is allowed to make a decision nor the amount that it charges before reaching a decision. 
Clearly this pathway takes years to travel, with uncertain cost but at the end, having a CE Mark 
allows sales on the open market. If the company could immediately start selling 1000s of devices per 
year, maybe such a large loan might be paid off but for devices that treat complex disabilities like 
spinal cord injury and stroke, the number of patients treated will be much fewer, initially at least. 
Clinicians must learn the surgical and therapeutic methods, as well, one hopes, as gaining confidence 
that it is a good treatment for appropriate patients. In the UK (population 65M), the total number of 
spinal injuries is about 1000 per year so an implant for treating incontinence in complete-lesion 
patients is unlikely to be suitable for more than 200 recent injuries per year and, however well the 
device worked, it is unlikely that one could reach this rate for, perhaps, ten years. It is very hard to 
see how a business case can be made. The interest payable on a loan of £10M will be at least £250k 
per year and if, for example, £2.5k of the sales prices of each device were paid back to the lender, 
one would have to sell 100 per year just to cover interest on the loan. Essentially the commercial 
problem is that the cost of regulatory process is so high that companies cannot reach a point where 
they break even. The device never gets past the so-called Valley of Death. 
As researchers, we can do something to help: we can look for grant funding with device 
development and preparation of the Technical File before the clinical trial; we can look for grant 
funding for the clinical trial; and we can study the benefits of the device after it is on the market in 
order to show clinicians at other centres that it is a good treatment, because this will advertise it to 
the customers. However, most companies that have tried to put neurological prostheses for small 
patient groups on the market have failed; I think that this is not because the technology was 
generally inadequate, nor because many patients have not liked them, but because of commercial 
difficulty which is getting worse as the regulations are tightened year by year. In the EU, the medical 
device Directives have just been superseded by the Medical Device Regulations which are generally 
expected to raise the bar even further1.  
Currently there are many research projects running for new types of implant for treating small 
patient groups: millions of pounds have been committed in research grants. These projects have 
great potential for improving quality of life, allowing disabled people greater freedom and ability to 
work, as well as reducing healthcare costs. But it is hard to see how they can get far beyond the 
research labs. The point of the regulations is consumer protection, to avoid risk to the patient, but 
the effect, I believe, has been to deprive severely impaired people of devices that we know were 
effective and this effect will continue in the EU in the future unless something is done.  
                                                          
1 In the annual prospectus for regulation, the BSI Director of Information Services wrote the following. “The 
changes … are likely to have considerable impact. With every single medical device currently on the market 
having to be evaluated for its suitability, manufacturers may decide that not every device in their portfolio is 
worth the time and expense this will take. Others may decide to pull out of the medical device market 
altogether.” (Bailey-Wood S, 2016) 
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Deregulation of devices for small patient groups is urgently needed to avoid further disappointment 
and wasted research effort and money. One way to do this would recognize that the open market is 
not a realistic description of sales for the first few hundred patients, or perhaps ever. The company 
is likely to supply only a small number of specialised rehabilitation centres, maintaining contact 
between the manufacturer and the clinicians. Patients can be followed closely, looking out for 
adverse effects. If such an arrangement were defined by agreement with the Competent Authority 
(MHRA), it seems reasonable that the company should be able to sell devices before getting a CE 
Mark. No doubt there are other possibilities. We should start by recognizing that the current system 
is economically unrealistic for small patient groups, which is bad for the patients and expensive for 
everybody. 
 
Nick Donaldson 
Professor of Neuroprosthesis Engineering 
University College London 
 
References 
Hamid R, Loveman C, Millen J, Globe D, Corbell C, Colayco D, Stanisic S & Gultyaev D, 2015, “Cost-
Effectiveness Analysis of OnabotulinumtoxinA (BOTOX) for the Management of Urinary Incontinence 
in Adults with Neurogenic Detrusor Overactivity: A UK Perspective.” Pharmacoeconomics, 33:381-
393. 
Brindley GS, 1994, “The first 500 patients with sacral anterior root stimulator implants: general 
description” Paraplegia, 32, 795-805. 
Demarchi J., IMPRESS Workshop, Leeds, October 2014. 
Kirkham APS, Knight SL, Craggs MD,  Casey ATM, & Shah PJR (2002)  “Neuromodulation through 
sacral nerve roots 2 and 4 with a Finetech-Brindley sacral posterior and anterior root stimulator” 
Spinal Cord, 40(6), 272-282. 
Tai CF, Roppolo JR, & De Groat WC (2004) “Block of external urethral sphincter contraction by high 
frequency electrical stimulation of pudendal nerve”, J. Urol., 172(5), 2069-2072. 
Bhadra N, Bhadra N & Kilgore K (2006) “High frequency electrical conduction block of the pudendal 
nerve” J. Neural Eng., 3(2), 180-186. 
Kilgore K & Bhadra N (2014) “Reversible Nerve Conduction Block Using Kilohertz Frequency 
Alternating Current” Neuromod., 17(3), 242-255. 
Metcalfe BW, Nielsen TN, Donaldson NdeN, Hunter AJ & Taylor JT “First Demonstration of Velocity 
Selective Recording from the Pig Vagus using a Nerve Cuff shows Respiration Afferents” Submitted 
2017. 
Bailey-Wood S, BSI Standards Outlook, 2016. 
 
 
